JEFFREY W. BODE studied Chemistry and Phylosophy at Trinity University in San Antonio, Texas. He performed his graduate work at the California Institute of Technology and ETH Zürich with Prof. Erick M. Carreira, followed by Postdoctoral Studies at the Tokyo Institute of Technology with Prof. Keisuke Suzuki. In 2003, he joined the University of California, Santa Barbara as an Assistant Professor of Chemistry and Biochemistry and in 2007 moved to the University of Pennsylvania in Philadelphia as an Associate Professor. In 2010, he returned to ETH Zürich as Professor of Synthetic Organic Chemistry. Since 2013, his group has also operated a satellite lab at the Institute of Transformative Biomolecules at Nagoya University in Japan. The fantastic and fearless students and postdocs working in the Bode Group develop new methods for the construction of modified biological molecules and apply these collaborations on fundamental biology and the development of new therapeutic modalities. By developing the alpha-ketoacid–hydroxylamine (KAHA) and potassium acyltrifluboroborate (KAT) ligations for chemoselective amide formation, the Bode group has pioneered new platforms for the chemical synthesis of proteins and biomolecular assemblies. The basic research and scientific insights from the Bode Group has led to the formation of three ETH spinoff companies – Synple Chem, Bright Peak Therapeutics, and Serac Biosciences.

Jeffrey is an Executive Editor of Encyclopedia of Reagents for Organic Synthesis. His research and teaching have been recognized by numerous awards including the Mukaiyama Award and the E. J. Corey Award. Currently, Jeffrey is the co-founder and Director of Studies for the new Biochemistry and Chemical Biology (BCB) Curriculum at ETH Zürich and a member of the Research Council of the Swiss National Science Foundation.